Novo Nordisk announced Monday that it will offer a new $499 monthly plan for U.S. patients with type 2 diabetes who pay out of pocket to access Ozempic. The initiative aims to improve affordability and availability of the company's semaglutide-based medicines.
- The program is available to self-paying patients in the U.S.
- Pricing is set at $499 per month for Ozempic.
- The offer will be accessible through multiple platforms, including telehealth provider GoodRx.
- Novo Nordisk described the move as part of broader efforts to expand access to semaglutide therapies.
Relevant Companies
- NVO – Novo Nordisk, maker of Ozempic, may see financial impact from increased patient adoption through this program.
- GDRX – GoodRx, which will distribute the offer via its telehealth platform, could benefit from higher user engagement.
- LLY – Eli Lilly, competitor with its obesity drug Mounjaro, could be affected by Novo Nordisk’s pricing move.
Editor’s Note: This is a developing story. This article may be updated as more details become available.
